SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes

Topics: 

Citation
Noergaard C et al.mEur Heart J 2019;40(Issue Supplement 1): ehz747.0054.